Approval moves Columvi earlier in DLBCL treatment pathway
A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for diffuse large B-cell lymphoma (DLBCL), the first in the class that can be used at this stage in the treatment pathway. The approval …